For patients with private drug insurance plans, out-of-pocket expenses, not the timing of patient reimbursements, have a greater affect on medication adherence.
For patients with private drug insurance plans, out-of-pocket expenses, not the timing of patient reimbursements, have a greater affect on medication adherence, according to a Canadian study. The study is important because while it is well known that medication nonadherence is a significant problem among patients with chronic diseases, and that drug insurance plans affect adherence, there was little evidence about the impact of reimbursement timing on medication adherence.
The study, published in the Journal of Managed Care & Specialty Pharmacy by Francois Despres, BSc, and colleagues at the University of Montreal, compared adherence to prescribed medications in privately insured patients from Quebec, Canada, with different timing of patient reimbursement and levels of out-of-pocket expenses. Patients in this study were 18 to 64 years of age and were in the reMed database from 2008 to 2012, which stores information related to prescribed medications filled at community pharmacies for a sample of Quebec residents. Each had filled at least 1 prescription for a medication belonging to 1 of the 10 most prescribed drug classes for chronic disease.
Patient reimbursement times were immediate (at the point of service of the portion of the cost covered by the insurer) or deferred (patient pays 100% of the medication costs at the pharmacy and receives reimbursement at a later time). Out-of-pocket expenses (including the deductible and coinsurance) were categorized into 5 levels (null category and quartiles) and adherence measured with the proportion of days covered over 1 year among new users of the medication studied.
The researchers estimated the adjusted mean differences of proportion of days covered between groups. They found there was no difference in medication adherence between the immediate (1345 patients) and deferred (437 patients) patient reimbursement groups (difference, 0.0%). Patients with the highest patient out-of-pocket expenses were less adherent than those with the lowest patient out-of-pocket expenses (difference, -19.0%; 95% CI, -24.0 to -13.0). The researchers noted that patients with no out-of-pocket expenses were actually less adherent than those with low out-of-pocket expenses (difference, -9.0%; 95% CI, -15.0 to -2.0).
The researchers said the lack of a correlation between medication adherence and the timing of patient reimbursement may be explained by the relatively rapid reimbursement of expenses by insurance companies in Canada. They hypothesize that patients in the study with no out-of-pocket expenses at the point of service might be less adherent to their medication regimen because they place less value on their medications than do people who must pay even a small amount.
The study was funded by Pfizer Canada.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More